BR102013001893A8 - antígenos recombinantes do porcine circovirus 2 (pcv-2) para formulações vacinais, kit de diagnóstico e uso - Google Patents

antígenos recombinantes do porcine circovirus 2 (pcv-2) para formulações vacinais, kit de diagnóstico e uso

Info

Publication number
BR102013001893A8
BR102013001893A8 BR102013001893A BR102013001893A BR102013001893A8 BR 102013001893 A8 BR102013001893 A8 BR 102013001893A8 BR 102013001893 A BR102013001893 A BR 102013001893A BR 102013001893 A BR102013001893 A BR 102013001893A BR 102013001893 A8 BR102013001893 A8 BR 102013001893A8
Authority
BR
Brazil
Prior art keywords
pcv
vaccine formulations
porcine circovirus
diagnostic kit
recombinant antigens
Prior art date
Application number
BR102013001893A
Other languages
English (en)
Other versions
BR102013001893A2 (pt
BR102013001893B1 (pt
Inventor
Silva Júnior Abelardo
Martins Da Cruz Souza Amanda
De Morais Monteiro Antônio
Costa Bressan Gustavo
De Andrade Teixeira Jackson
Souza Crispim Josicelli
Lopes Rangel Fietto Juliana
Fernando Lino De Souza Luiz
Costa Fausto Mariana
Rogéria De Almeida Lamêgo Márcia
Fialho Gonzaga Natália
Marcus Pereira Vidigal Pedro
Locatelli Salgado Rafael
Amaziles Silva Leite Roberta
Patareli Kalks Sthefany
Souza Onofre Thiago
Jaquel Zilch Tiago
Original Assignee
Fapemig Fund De Amparo A Pesquisa Do Estado De Minas Gerais
Univ Federal Vicosa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fapemig Fund De Amparo A Pesquisa Do Estado De Minas Gerais, Univ Federal Vicosa filed Critical Fapemig Fund De Amparo A Pesquisa Do Estado De Minas Gerais
Priority to BR102013001893-7A priority Critical patent/BR102013001893B1/pt
Priority to UY0001035272A priority patent/UY35272A/es
Priority to RU2015135619A priority patent/RU2687001C2/ru
Priority to EP14742935.1A priority patent/EP2949341B1/en
Priority to US14/763,121 priority patent/US9717785B2/en
Priority to CN201480006177.0A priority patent/CN105263515A/zh
Priority to MX2015009507A priority patent/MX362820B/es
Priority to ES14742935T priority patent/ES2792510T3/es
Priority to PCT/BR2014/000019 priority patent/WO2014113855A1/pt
Priority to ARP140100223A priority patent/AR094578A1/es
Publication of BR102013001893A2 publication Critical patent/BR102013001893A2/pt
Priority to CO15164030A priority patent/CO7461131A2/es
Priority to US14/875,090 priority patent/US20160015799A1/en
Publication of BR102013001893A8 publication Critical patent/BR102013001893A8/pt
Publication of BR102013001893B1 publication Critical patent/BR102013001893B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56983—Viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/10011—Circoviridae
    • C12N2750/10023—Virus like particles [VLP]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/10011—Circoviridae
    • C12N2750/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/01—DNA viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
    • G01N2333/01—DNA viruses
    • G01N2333/015—Parvoviridae, e.g. feline panleukopenia virus, human Parvovirus
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00—Immunoassays for the detection of microorganisms
    • G01N2469/20—Detection of antibodies in sample from host which are directed against antigens from microorganisms

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)

Abstract

antígenos recombinantes do porcine circovirus 2 (pcv-2) para formulações vacinais, kit de diagnóstico e uso. a presente invenção se refere à obtenção do antígeno recombinante do capsídeo viral do porcine circovirus 2 (pcv-2) e suas modificações, mediante expressão em sistema procariótico, purificação na forma monomérica, recuperação de partículas semelhantes a vírus (vlps) e sua utilização em formulações vacinais, kits de diagnóstico e num sistema de quantificação nas partidas vacinais do antígeno do pcv-2 por meio de um elisa de captura. os antígenos e as formulações vacinais podem ser empregados na imunização de animais em programas de controle das doenças associadas ao pcv-2 nos sistemas de produção de suínos convencionais e representam alternativas às vacinas disponíveis no mercado. o kit de elisa pode ser empregado para testes de qualidade em vacinas comerciais e/ou experimentais contra o pcv-2.
BR102013001893-7A 2013-01-25 2013-01-25 Antígenos recombinantes do porcine circovirus 2 (pcv-2) para formulações vacinais, kit de diagnóstico e uso BR102013001893B1 (pt)

Priority Applications (12)

Application Number Priority Date Filing Date Title
BR102013001893-7A BR102013001893B1 (pt) 2013-01-25 2013-01-25 Antígenos recombinantes do porcine circovirus 2 (pcv-2) para formulações vacinais, kit de diagnóstico e uso
UY0001035272A UY35272A (es) 2013-01-25 2014-01-20 ?antígenos recombinantes del porcine circovirus 2 (pcv-2) para formulaciones de vacuna, kit de diagnóstico y uso?.
ES14742935T ES2792510T3 (es) 2013-01-25 2014-01-23 Antígenos recombinantes del circovirus porcino 2 (PCV-2) para formulaciones de vacuna, kit de diagnóstico y uso de los mismos
EP14742935.1A EP2949341B1 (en) 2013-01-25 2014-01-23 Recombinant antigens of porcine circovirus 2 (pcv-2) for vaccine formulations, diagnostic kit and use thereof
US14/763,121 US9717785B2 (en) 2013-01-25 2014-01-23 Recombinant antigens of porcine circovirus 2 (PCV-2) for vaccine formulations, diagnostic kit and use thereof
CN201480006177.0A CN105263515A (zh) 2013-01-25 2014-01-23 用于疫苗制剂、诊断试剂盒的重组猪圆环病毒2(pcv-2)的抗原及其使用
MX2015009507A MX362820B (es) 2013-01-25 2014-01-23 Antígenos recombinantes del circovirus porcino tipo 2 (pcv-2) para formulaciones de vacuna, kit de diagnóstico y uso.
RU2015135619A RU2687001C2 (ru) 2013-01-25 2014-01-23 Рекомбинантные антигены цирковируса свиней типа 2 (pcv-2) для композиций вакцин, диагностический набор и их применение
PCT/BR2014/000019 WO2014113855A1 (pt) 2013-01-25 2014-01-23 Antígenos recombinantes do porcine circovirus 2 (pcv-2) para formulações vacinais, kit de diagnóstico e uso
ARP140100223A AR094578A1 (es) 2013-01-25 2014-01-24 Antígenos recombinantes del porcine circovirus 2 (pcv-2) para formulaciones de vacuna, kit de diagnóstico y uso
CO15164030A CO7461131A2 (es) 2013-01-25 2015-07-15 Antígenos recombinantes del porcine circovirus 2 (pcv-2) para formulaciones de vacuna, kit de diagnóstico y uso
US14/875,090 US20160015799A1 (en) 2013-01-25 2015-10-05 Recombinant antigens of the porcine circovirus 2 (pcv-2) for vaccine formulations and use thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
BR102013001893-7A BR102013001893B1 (pt) 2013-01-25 2013-01-25 Antígenos recombinantes do porcine circovirus 2 (pcv-2) para formulações vacinais, kit de diagnóstico e uso

Publications (3)

Publication Number Publication Date
BR102013001893A2 BR102013001893A2 (pt) 2014-09-09
BR102013001893A8 true BR102013001893A8 (pt) 2017-12-05
BR102013001893B1 BR102013001893B1 (pt) 2022-01-25

Family

ID=51226766

Family Applications (1)

Application Number Title Priority Date Filing Date
BR102013001893-7A BR102013001893B1 (pt) 2013-01-25 2013-01-25 Antígenos recombinantes do porcine circovirus 2 (pcv-2) para formulações vacinais, kit de diagnóstico e uso

Country Status (11)

Country Link
US (2) US9717785B2 (pt)
EP (1) EP2949341B1 (pt)
CN (1) CN105263515A (pt)
AR (1) AR094578A1 (pt)
BR (1) BR102013001893B1 (pt)
CO (1) CO7461131A2 (pt)
ES (1) ES2792510T3 (pt)
MX (1) MX362820B (pt)
RU (1) RU2687001C2 (pt)
UY (1) UY35272A (pt)
WO (1) WO2014113855A1 (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106478783B (zh) * 2015-08-24 2021-11-02 兆丰华生物科技(南京)有限公司北京生物医药科技中心 一种猪圆环病毒ii型基因工程亚单位疫苗及其应用
CN105541976B (zh) * 2015-12-25 2019-07-09 华南农业大学 猪圆环病毒2型Cap基因修饰改造重组抗原及其应用
CN109425738B (zh) * 2017-09-01 2022-01-28 洛阳普泰生物技术有限公司 猪圆环病毒3型抗体检测试剂盒及其应用
CN109187774B (zh) * 2018-07-03 2021-09-28 复旦大学 一种猪圆环病毒2型病毒样颗粒的定量检测方法
CN110981945B (zh) * 2019-12-08 2021-10-19 中牧实业股份有限公司 一种猪圆环病毒2型重组Cap蛋白的表达制备及应用
CN111233983A (zh) * 2020-02-26 2020-06-05 郭广君 猪圆环病毒cap蛋白一步法大规模纯化及内毒素去除工艺
CN114354526A (zh) * 2021-12-28 2022-04-15 国药集团动物保健股份有限公司 一种猪圆环病毒3型纯品蛋白的定量检测方法
CN114805501B (zh) * 2022-03-24 2024-06-25 中牧实业股份有限公司 一种猪圆环病毒2型抗原组合物及其在抗原定量方法中的应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2769322B1 (fr) * 1997-10-03 2002-03-08 Merial Sas Nouveaux circovirus porcins, vaccins et reactifs de diagnostic
WO1999045956A1 (en) 1998-03-13 1999-09-16 University Of Georgia Research Foundation, Inc. Vaccines against circovirus infections
WO2005009462A2 (en) 2003-07-24 2005-02-03 Merial Limited Vaccine formulations comprising an oil-in-water emulsion
US7700285B1 (en) 2005-12-29 2010-04-20 Boehringer Ingelheim Vetmedica, Inc. PCV2 immunogenic compositions and methods of producing such compositions
CN101277717A (zh) 2005-09-09 2008-10-01 英特威国际有限公司 Pcv-2疫苗
JP5394750B2 (ja) 2005-12-29 2014-01-22 ベーリンガー インゲルハイム フェトメディカ インコーポレイテッド 多価ｐｃｖ２免疫原性組成物及び当該組成物を製造する方法
ME01156B (me) * 2007-12-21 2013-03-20 Zoetis Services Llc Postupci i kompozicije za imunizaciju svinja protiv svinjskog cirkovirusa
EA201100862A1 (ru) * 2008-11-28 2012-01-30 Сева Санте Анималь Новый изолят свиного цирковируса типа 2b и его применения
BR112012009212A2 (pt) * 2009-10-22 2017-06-20 Univ Leipzig 'aplasia de medula óssea com doença hemorrágica em bezerros causada por um novo agente patogênico"
CN102174086B (zh) * 2011-03-07 2014-04-02 南京农业大学 一种猪圆环病毒2型重组Cap蛋白和亚单位疫苗
CN102911947A (zh) * 2011-08-01 2013-02-06 普莱柯生物工程股份有限公司 猪圆环病毒2型Cap蛋白及其制备方法
CN102839195A (zh) * 2012-07-18 2012-12-26 华南农业大学 利用pFast Bac Dual杆状病毒表达PCV 2 Cap蛋白的方法

Also Published As

Publication number Publication date
WO2014113855A1 (pt) 2014-07-31
RU2015135619A (ru) 2017-03-10
AR094578A1 (es) 2015-08-12
US9717785B2 (en) 2017-08-01
CO7461131A2 (es) 2015-11-30
EP2949341B1 (en) 2020-04-01
US20160000897A1 (en) 2016-01-07
EP2949341A4 (en) 2016-07-27
RU2687001C2 (ru) 2019-05-06
BR102013001893A2 (pt) 2014-09-09
EP2949341A1 (en) 2015-12-02
MX362820B (es) 2019-02-18
CN105263515A (zh) 2016-01-20
UY35272A (es) 2014-08-29
ES2792510T3 (es) 2020-11-11
US20160015799A1 (en) 2016-01-21
MX2015009507A (es) 2016-04-07
BR102013001893B1 (pt) 2022-01-25

Similar Documents

Publication Publication Date Title
BR102013001893A8 (pt) antígenos recombinantes do porcine circovirus 2 (pcv-2) para formulações vacinais, kit de diagnóstico e uso
Zhang et al. Identification of an ideal adjuvant for receptor-binding domain-based subunit vaccines against Middle East respiratory syndrome coronavirus
Ma et al. Intranasal vaccination with recombinant receptor-binding domain of MERS-CoV spike protein induces much stronger local mucosal immune responses than subcutaneous immunization: Implication for designing novel mucosal MERS vaccines
Suschak et al. A cGAS-independent STING/IRF7 pathway mediates the immunogenicity of DNA vaccines
Maroof et al. Intranasal vaccination promotes detrimental Th17-mediated immunity against influenza infection
Chung et al. ISCOMATRIX™ adjuvant promotes epitope spreading and antibody affinity maturation of influenza A H7N9 virus like particle vaccine that correlate with virus neutralization in humans
Gupta et al. HPV vaccines: Global perspectives
Rosendahl Huber et al. Synthetic long peptide influenza vaccine containing conserved T and B cell epitopes reduces viral load in lungs of mice and ferrets
WO2014150822A3 (en) Porcine reproductive and respiratory syndrome virus, compositions, vaccine and methods of use
BR112016023778A2 (pt) proteína de fusão ou coquetel antígeno, uso de uma proteína de fusão ou coquetel antígeno, vacina, e método para a imunização de um animal, incluindo um ser humano, contra a tuberculose causada por micobactérias virulentas
BR112018075513A2 (pt) ácidos nucleicos que codificam as partículas seme-lhantes ao vírus da zika e seu uso nas vacinas e no ensaio de diagnóstico do vírus da zika
Valero-Pacheco et al. Antibody persistence in adults two years after vaccination with an H1N1 2009 pandemic influenza virus-like particle vaccine
Chen et al. Synthetic B-and T-cell epitope peptides of porcine reproductive and respiratory syndrome virus with Gp96 as adjuvant induced humoral and cell-mediated immunity
De Vleeschauwer et al. A canine adenovirus type 2 vaccine vector confers protection against foot-and-mouth disease in guinea pigs
NO20074855L (no) Anvendelse av et modifisert poxvirus for den rapide induksjonen av immunitet mot et poxvirus eller andre smittsomme midler
Kochinger et al. Vesicular stomatitis virus replicon expressing the VP2 outer capsid protein of bluetongue virus serotype 8 induces complete protection of sheep against challenge infection
WO2018066999A3 (en) Chimeric enterovirus virus-like particles
Tabynov et al. Duration of the protective immune response after prime and booster vaccination of yearlings with a live modified cold-adapted viral vaccine against equine influenza
BR132016015841E2 (pt) antígenos recombinantes do porcine circovirus 2 (pcv-2) para formulações vacinais e uso
Hernandez et al. Particle and subunit-based hemagglutinin vaccines provide protective efficacy against H1N1 influenza in pigs
Pyo et al. Protective efficacy of intranasally administered bivalent live influenza vaccine and immunological mechanisms underlying the protection
Yokomine et al. Enhancement of humoral and cell mediated immune response to HPV16 L1-derived peptides subsequent to vaccination with prophylactic bivalent HPV L1 virus-like particle vaccine in healthy females
BR112015004085A2 (pt) método para cultivar uma cepa de rotavírus (rv); método para gerar uma rv3 atenuada em células vero; rv3 adaptada à vero isolada; composição de rv morto ou vivo atenuado; método para vacinar um indivíduo humano contra infecção por rv; método para tratar um indivíduo humano com uma infecção por rv ou em risco de desenvolver uma infecção ou reinfecção por rv; uso da rv3 de vero; anticorpo isolado; e método para detectar ou monitorar a rv3 de vero
WO2016179099A4 (en) Modified h7 hemagluttinin glycoprotein of the influenza a/shanghai/2/2013 h7 sequence
TWI490229B (zh) 豬瘟病毒封套醣蛋白Ｅｒｎｓ之特異性單株抗體ＣＷ８１３及其於間接三明治ＥＬＩＳＡ抗體檢測之應用

Legal Events

Date Code Title Description
B03A Publication of a patent application or of a certificate of addition of invention [chapter 3.1 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B25G Requested change of headquarter approved

Owner name: UNIVERSIDADE FEDERAL DE VICOSA (BR/MG) , FAPEMIG -

B25E Requested change of name of applicant rejected

Owner name: UNIVERSIDADE FEDERAL DE VICOSA (BR/MG) , FAPEMIG -

B03H Publication of an application: rectification [chapter 3.8 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 25/01/2013, OBSERVADAS AS CONDICOES LEGAIS.